Sarepta falls after preliminary Q4 Elevidys revenue misses estimates

Sarepta Therapeutics

12/01/2026 18:30

** Shares of genetic medicine maker Sarepta Therapeutics SRPT.O fall 12.26% to $20.91

** SRPT reports preliminary Q4 Elevidys net product revenue of $110.4 mln vs analysts' estimate of $176.99 mln, according to data compiled by LSEG

** Reports preliminary FY25 Elevidys net product revenue of $898.7 mln vs analysts' estimate of $1,029 mln

** "ELEVIDYS fourth-quarter revenue was impacted by severe year-end flu season and the need in December to reschedule 6 patient infusions into 2026", co says

** Co reconfirms previously set yearly sales floor for ELEVIDYS of $500 million

** Stock had fallen 82.3% in 2025

 (Reporting by Megha Anilkumar Nair)

 ((MeghaAnilkumar.Nair@thomsonreuters.com;))